# Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease

> **NCT02469701** · PHASE2 · TERMINATED · sponsor: **howard safran** · enrollment: 10 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Lung Cancer
- Metastatic Lung Cancer
- NSCLC

## Interventions

- **DRUG:** nivolumab and ablation

## Key facts

- **NCT ID:** NCT02469701
- **Lead sponsor:** howard safran
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02
- **Primary completion:** 2017-07
- **Final completion:** 2018-03
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2020-02-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02469701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02469701, "Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02469701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*